3 Minutes To Boost Your Earnings: 3 Stocks With Over 3% Dividend Yields In Health Care Sector From Wall Street's Most Accurate Analysts

During times of turbulence and uncertainty in the markets, many investors turn to dividend-yielding stocks. These are often companies that have high free cash flows and reward shareholders with a high dividend payout.

Benzinga readers can review the latest analyst takes on their favorite stocks by visiting our Analyst Stock Ratings page. Traders can sort through Benzinga's extensive database of analyst ratings, including by analyst accuracy. Here's a look at the most recent high-yield dividend stock ratings from the most accurate Wall Street analysts, according to Benzinga's Analyst Stock Ratings.

Below are the ratings of the most accurate analysts for three high-yielding stocks in the health care sector.

Organon & Co. OGN

• Dividend Yield: 7.93%
• Piper Sandler analyst David Amsellem maintained an Overweight rating and cut the price target from $32 to $22 on Nov. 22, 2023. This analyst has an accuracy rate of 64%.
• Morgan Stanley analyst Terence Flynn maintained an Equal-Weight rating and lowered the price target from $27 to $22 on Oct. 11, 2023. This analyst has an accuracy rate of 66%.
• Recent News: Organon became sole distributor and promoter for Eli Lilly's migraine medicines Emgality (Galcanezumab) and Rayvow (Lasmiditan) in Europe.

Viatris Inc. VTRS

• Dividend Yield: 4.48%
• Piper Sandler analyst David Amsellem maintained a Neutral rating and raised the price target from $10 to $11 on Nov. 22, 2023. This analyst has an accuracy rate of 64%.
• B of A Securities analyst Jason Gerberry downgraded the stock from Neutral to Underperform with a price target of $9 on Oct. 23, 2023. This analyst has an accuracy rate of 70%.
• Recent News: Viatris announced the appointment of Theodora "Doretta" Mistras as Chief Financial Officer, effective March 1, 2024, and Philippe Martin as Chief R&D Officer with immediate effect.

CVS Health Corporation CVS

• Dividend Yield: 3.37%
• RBC Capital analyst Ben Hendrix maintained an Outperform rating and cut the price target from $91 to $86 on Nov. 2, 2023. This analyst has an accuracy rate of 61%.
• Morgan Stanley analyst Erin Wright maintained an Overweight rating and slashed the price target from $110 to $100 on Nov. 2, 2023. This analyst has an accuracy rate of 77%.
• Recent News: CVS Health recently reiterated FY23 guidance, issued FY24 guidance and announced a quarterly dividend of 66.5 cents per share.

Read More: Broadcom, Intuit And 2 Other Stocks Insiders Are Selling